Literature DB >> 29794562

Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.

Donatella Iacono1, Marika Cinausero1,2, Lorenzo Gerratana1,2, Vito Angione3, Cathryn Anne Scott4,2, Giovanna De Maglio3, Stefano Pizzolitto3, Carla Di Loreto4,2, Fabio Puglisi2,5, Gianpiero Fasola1, Alessandro Marco Minisini1.   

Abstract

Age is an important prognostic factor in melanoma; notably, elderly patients tend to present with advanced stage skin melanoma (SM) and worse outcome. Moreover, SM is an immunogenic cancer, and its interaction with the aging immune system could have an effect on biologic behaviour of this disease. Tumour-infiltrating lymphocytes (TILs) could represent the host response in SM; it has been shown that higher grade of TILs is associated with better survival. Moreover, programmed death ligand 1 (PD-L1) and cyclooxygenase-2 (COX-2) are potential markers of host immune response and inflammation. We retrospectively reviewed 113 consecutive cases of early-stage SM that occurred in patients aged greater than or equal to 65 years at the time of diagnosis, followed between January 2010 and March 2014 at the University and General Hospital of Udine, Italy. The aim of this study was to evaluate TILs grade, PD-L1 expression on TILs and tumour expression of PD-L1 and COX-2 and their prognostic value in elderly patients with early SM. A better disease-free survival as well as melanoma-specific survival (MSS) was significantly associated with TILs [hazard ratios (HR): 0.41, 95% confidence interval (CI): 0.20-0.84, P=0.02 and HR: 0.37, 95% CI: 0.17-0.82, P=0.01, respectively]. PD-L1 positivity on TILs was associated with a better MSS (HR: 0.41, 95% CI: 0.17-0.97, P=0.04). Moreover, among patients with TILs, those showing COX-2 positivity on tumour cells and no PD-L1 expression on TILs had a worse disease-free survival and MSS (HR: 5.18, 95% CI: 1.33-20.23, P=0.018; HR: 6.21, 95% CI: 1.20-32.24, P=0.03; respectively). Immune and inflammatory markers deserve further investigation in aging patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29794562     DOI: 10.1097/CMR.0000000000000462

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  4 in total

Review 1.  Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Authors:  Dongkui Song; Thomas Powles; Lei Shi; Lirong Zhang; Molly A Ingersoll; Yong-Jie Lu
Journal:  J Pathol       Date:  2019-06-24       Impact factor: 7.996

2.  PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.

Authors:  Sandra Lassalle; Sacha Nahon-Esteve; Eric Frouin; Camille Boulagnon-Rombi; Nicolas Josselin; Nathalie Cassoux; Raymond Barnhill; Boris Scheller; Stéphanie Baillif; Paul Hofman
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

3.  Low Doses of Celecoxib Might Promote Phenotype Switching in Cutaneous Melanoma Treated with Dabrafenib-Preliminary Study.

Authors:  Diana Valentina Tudor; Adrian Florea; Mihai Cenariu; Diana Elena Olteanu; Marius Farcaș; Andreea Hopârtean; Simona Valeria Clichici; Gabriela Adriana Filip
Journal:  J Clin Med       Date:  2022-08-04       Impact factor: 4.964

Review 4.  COX-2 as a potential biomarker and therapeutic target in melanoma.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Mihai Lupu; Teodor Kacso; Eniko Kutasi; Andreea Hopârtean; Roland Stretea; Adriana Gabriela Filip
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.